Drug Profile


Alternative Names: GEO-D03 DNA vaccine; GeoVax Clade B DNA/MVA HIV/AIDS Vaccine; GOVX-B; pGA2-JS7 + MVA/HIV62

Latest Information Update: 10 Feb 2017

Price : $50

At a glance

  • Originator GeoVax Labs; National Institute of Allergy and Infectious Diseases
  • Developer GeoVax Labs
  • Class AIDS vaccines; DNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II HIV infections

Most Recent Events

  • 23 Jan 2017 GeoVax initiates a phase I (HVTH 114) trial for HIV infections (Prevention) in USA (NCT02852005)
  • 05 Aug 2016 US FDA approves IND application for GOVX B11 in HIV infections (Prevention)
  • 30 Jun 2016 GeoVax files an IND application with the US FDA for HIV infections (Prevention) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top